Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).

被引：2
|
作者：
Ghatalia, Pooja
Handorf, Elizabeth A.
Deng, Mengying
Zibelman, Matthew R.
Abbosh, Philip
Anari, Fern
Greenberg, Richard E.
Viterbo, Rosalia
Chen, David
Smaldone, Marc C.
Kutikov, Alexander
Geynisman, Daniel M.
Uzzo, Robert Guy
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] FCCC, Philadelphia, PA USA
[3] Fox Chase Canc Ctr, Dept Hematol & Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[4] Temple Univ Hlth Syst, Fox Chase Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.4582
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4582
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Preoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)
    Finelli, A.
    Horgan, A. M.
    Evans, A.
    Kim, T. K.
    Durrant, K.
    Yap, S.
    Cassol, C. A.
    Dubinski, W.
    Fleshner, N.
    Jewett, M. A. S.
    Joshua, A. M.
    Sridhar, S. S.
    Zlotta, A.
    Knox, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] External validation of a prediction model of survival after cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC).
    Bex, Axel
    van Werkhoven, Erik D.
    Noe, Allard
    Karam, Jose A.
    Matin, Surena F.
    Margulis, Vitaly
    Stewart, Grant
    Staehler, Michael D.
    Wood, Christopher G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] Outcome of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN)
    Richey, S. L.
    Culp, S. H.
    Jonasch, E.
    Corn, P. G.
    Pagliaro, L. C.
    Matin, S. F.
    Wood, C. G.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN)
    Richey, S. L.
    Culp, S. H.
    Wood, C. G.
    Corn, P. G.
    Jonasch, E.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] CABOPRE: A phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)
    De Velasco, G.
    Alonso-Gordoa, T.
    Rodriguez-Moreno, J. F.
    Duran, I.
    Carretero-Gonzalez, A.
    Martin-Soberon, M.
    Gutierrez Banos, J. L.
    Guerrero-Ramos, F.
    Duenas, M.
    Castellano Gauna, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S698 - S699
  • [6] Cytoreductive nephrectomy in advanced or metastatic renal cell carcinoma (mRCC): In the era of targeted strategies
    Toutziaris, C.
    Lontovinis, L.
    Tsoukalas, N.
    Radopoulos, D.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 78 : S26 - S26
  • [7] The role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Alnimer, Yanal Mufeed
    Qasrawi, Ayman
    Katato, Khalil
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma
    Umbreit, Eric C.
    McIntosh, Andrew G.
    Suk-Ouichai, Chalairat
    Karam, Jose A.
    Wood, Christopher G.
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (01) : 13 - 16
  • [9] Commentary on the role of cytoreductive nephrectomy in metastatic renal cell carcinoma
    Schulz, Gerald
    AKTUELLE UROLOGIE, 2023, 54 (03) : 180 - 181
  • [10] The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma
    Graham, Jeffrey
    Bhindi, Bimal
    Heng, Daniel Y. C.
    CURRENT OPINION IN UROLOGY, 2019, 29 (05) : 507 - 512
12345